OBJECTIVES: There is growing evidence in the literature supporting the association between tobacco smoking and poor tuberculosis (TB) treatment outcomes. Connecting TB and tobacco cessation interventions has been strongly advocated as this may produce significant benefits. However, no study has documented the impact of such integration on health-related quality of life (HRQoL). The objective of the study was to document the impact of an integrated TB directly observed therapy short-course (DOTS) plus smoking cessation intervention (SCI) on HRQoL.  METHODS: This was a non-randomized controlled study (quasi experimental design) involving 120 TB patients who were current smokers at the time of TB diagnosis. Patients were assigned to either of two groups: conventional TB-DOTS plus smoking cessation intervention (SCIDOTS group) or conventional TB-DOTS only (DOTS group). The effects of the novel intervention on HRQoL were measured using EQ-5D questionnaire. Two-way repeated measure ANOVA was used to examine the effects. RESULTS: When compared, participants who received the integrated intervention had a better HRQoL than those who received the conventional TB care. The SCIDOTS group had a significantly greater increase in EQ-5D utility score than the DOTS group during 6 months follow-up (mean ± SD = 0.98 ± 0.08 vs. 0.91 ± 0.14, p = 0.006). Similarly, the mean scores for EQ-VAS showed a consistently similar trend as the EQ-5D indices, with the scores increasing over the course of TB treatment. Furthermore, for the EQ-VAS, there were significant main effects for group [F (1, 84) = 4.91, p = 0.029, η2 = 0.06], time [F (2, 168) = 139.50, p = <0.001, η2 = 0.62] and group x time interaction [F (2, 168) = 13.89, p = <0.001, η2 = 0.14]. CONCLUSIONS: This study provides evidence that an integrated TB-tobacco treatment strategy could potentially improve overall quality of life outcomes among TB patients who are smokers.